[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR048315A1 - Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. - Google Patents

Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.

Info

Publication number
AR048315A1
AR048315A1 ARP050100899A ARP050100899A AR048315A1 AR 048315 A1 AR048315 A1 AR 048315A1 AR P050100899 A ARP050100899 A AR P050100899A AR P050100899 A ARP050100899 A AR P050100899A AR 048315 A1 AR048315 A1 AR 048315A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally
alkoxy
substituted
cr7r8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP050100899A
Other languages
English (en)
Inventor
Ming Hong Hao
Victor Kamhi
Matthew Netherton
Alan D Swinamer
Creig Andrew Miller
Derek A Cogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR048315A1 publication Critical patent/AR048315A1/es
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)

Abstract

Compuestos descriptos de la formula (1), que inhiben la produccion de citocinas implicadas en procesos inflamatorios y que, por lo tanto, son utiles para tratar enfermedades y afecciones patologicas que implican inflamacion, como la enfermedad inflamatoria cronica. También se describen composiciones farmacéuticas que comprenden estos compuestos utilizables para el tratamiento de enfermedades oncologicas además de las ya mencionadas. Reivindicacion 1: Un compuesto de la formula (1), en el que: Ar1 se selecciona entre i), ii) y iii) a continuacion: i) un carbociclo sustituido con R1, R2 y Rx; ii) una formula (2), en el que uno de E o F es nitrogeno y el otro es carbono, R1 está covalentemente unido o bien a E o F y, cuando nitrogeno es N-R1, no está presente el enlace doble entre E y F; iii) una formula (3) en el que c es un anillo benzo condensado al anillo d que es un anillo heterocíclico de 5-7 miembros opcionalmente sustituido con un grupo oxo (=O), y uno a dos grupos R, siendo cada uno independientemente H o alquilo C1-3; R1 se selecciona entre hidrogeno, NO2, -N(Rc)2, J-C(O)-N(Rc)-, J-S(O)m-N(Rc)-, alquiloC1-6S(O)m-; o R1 se selecciona entre alquilo C1-6, cicloalquilo C3-7, alcoxilo C1-5 o cicloalcoxilo C3-7, alquiltiol C1-5 o cicicloalquiltiol C3-7, acilo C1-5, alcoxicarbonilo C1-5, aciloxi C1-5, acilamino C1-5, alquenilo C2-5, alquinilo C2-5, heterociclo, heterocicloalquilo C1-6, heteroarilo, heteroarilalquilo C1-6 y nitrilo; cada uno de los anteriormente mencionados, cuando es posible, está opcionalmente parcial o totalmente halogenado o está opcionalmente sustituido además con alquilsulfonilamino, aminocarboxilo, alcoxilo, amino, alquilamino, dialquilamino, hidroxilo, oxo, nitro o nitrilo; R2 se selecciona entre: hidrogeno, halogeno, nitrilo, alquiloC1-5S(O)m-, ariloS(O)m, J-O-C(O)-O-, N(Rc)2-C(O)-(CH2)n-, acetilo C1-6, aroilo, alcoxicarbonilo C1-6, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, cicloalcoxi C3-5, alquilo C1- 5alcoxiC1-5, hidroxi, hidroxialquilo C1-5 y amino opcionalmente mono o di-sustituido C1-5, arilo o arilalquilo C1-5; cada uno de los ya mencionados, cuando es posible, está opcionalmente parcial o totalmente halogenado u opcionalmente también sustituido con alquilo C1-3, alquilsulfonilamino, alcoxilo, amino, alquilamino, dialquilamino, hidroxilo, oxo, nitro o nitrilo; cada Rx se selecciona entre alquilo C1-6 o cicloalquilo C3-7, estando cada uno opcionalmente sustituido con alquilo C1-3 y opcionalmente parcial o totalmente halogenado, acilo C1-4, aroilo, alcoxi C1-4, alquiloC1-5S(O)m-, en los que cada uno puede estar opcionalmente parcial o totalmente halogenado, halogeno, alcoxicarbonilo C1-6, carbociclosulfonilo; cada Rc es indepedientemente hidrogeno o alquilo C1-5; D, A y B del resto de formula (4) de la formula (1) se seleccionan cada uno independientemente entre N o CH, en los que el átomo de hidrogeno está opcionalmente reemplazado con R6; Het es un anillo de heteroarilo o heterocíclico, en el que Het está opcionalmente sustituido con uno a tres R5; m es 0, 1 o 2; J se selecciona entre alquilo C1-10 y cicloalquilo C3-7, cada uno opcionalmente sustituido con Rb; R3, R4, R6, R7 y R8 se seleccionan cada uno independientemente entre hidrogeno, halogeno, alquilo C1-5, alcoxi C1-5, alquiloC1-5alcoxiC1-5, hidroxi, hidroxialquilo C1-5 o amino opcionalmente mono o di-sustituido con alquilo C1-5, arilo o arilalquilo C1-5; R5 es: Ra, -O-Ra, -S(O)m-Ra, -N(Ra)2, -C(O)-Ra, -NH(CR7R8)n-Ra, N(Ra)2-(CH2)1-2-, -(CR7R8)n-Ra, -O(CR7R8)n-Ra, -C(O)-O(CR7R8)n-Ra, -C(O)(CR7R8)n-Ra, -C(O)C(O)Ra, -C(O)C(O)ORa, -C(O)NHRa o -C(O)NH(CR7R8)n-, cada uno opcionalmente sustituido con alquilo C1-3, halogeno o hidroxi; en los que n es 1-5; o R5 es arilo, heteroarilo o heterociclilo, cada uno opcionalmente sustituido con Ra; Ra y Rb se seleccionan cada uno independientemente entre hidrogeno, alquilo C1-6, hidroxialquilo C1-5, alquenilo C2-5, alquinilo C2-5, carbociclo, carbocicloalquilo C0-2, arilo, heterociclo, heteroarilo, alcoxi C1-5, alquiltio C1-5, amino, alquilamino C1-5, dialquilamino C1-5, arilamino, arilalquilamino C1-5, diarilamino, acilo C1-5, alcoxicarbonilo C1-5, aciloxi C1-5, acilamino C1-5, en los que cada uno de los ya mencionados está opcionalmente parcial o totalmente halogenado, o Ra y Rb se seleccionan entre alquilsulfonilamino C1-5, hidroxi, oxo, halogeno, CF3, -CH2-CF3, nitro y nitrilo, en los que cada carbociclo, heterociclo o heteroarilo C1-3, halogeno o hidroxi; y X es O o S; o sus sales farmacéuticamente aceptables.
ARP050100899A 2004-03-09 2005-03-09 Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. Pending AR048315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09

Publications (1)

Publication Number Publication Date
AR048315A1 true AR048315A1 (es) 2006-04-19

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100899A Pending AR048315A1 (es) 2004-03-09 2005-03-09 Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.

Country Status (30)

Country Link
US (2) US7214802B2 (es)
EP (2) EP1725544B1 (es)
JP (1) JP4850824B2 (es)
KR (1) KR20060129077A (es)
CN (1) CN1930144A (es)
AR (1) AR048315A1 (es)
AT (1) ATE432273T1 (es)
AU (1) AU2005223738B2 (es)
BR (1) BRPI0508561A (es)
CA (1) CA2557856C (es)
CY (1) CY1109333T1 (es)
DE (1) DE602005014621D1 (es)
DK (1) DK1725544T3 (es)
EA (1) EA011634B1 (es)
EC (1) ECSP066833A (es)
ES (1) ES2327940T3 (es)
HR (1) HRP20090334T1 (es)
IL (1) IL177937A0 (es)
MY (1) MY143000A (es)
NO (1) NO20064120L (es)
NZ (1) NZ550148A (es)
PE (1) PE20051146A1 (es)
PL (1) PL1725544T3 (es)
PT (1) PT1725544E (es)
RS (1) RS50796B (es)
SI (1) SI1725544T1 (es)
TW (1) TW200602313A (es)
UA (1) UA85702C2 (es)
WO (1) WO2005090333A1 (es)
ZA (1) ZA200606177B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536618A (ja) * 2006-04-18 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4−及び5−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
EA200900072A1 (ru) * 2006-07-07 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
CN101511796B (zh) 2006-09-05 2012-05-09 协和发酵麒麟株式会社 咪唑衍生物
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
JP2010531850A (ja) * 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2009070304A1 (en) 2007-11-27 2009-06-04 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
WO2009123753A1 (en) 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
US7897631B2 (en) * 2008-04-21 2011-03-01 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
JP2012501317A (ja) * 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ トリアゾール誘導体、及びそのニコチン性アセチルコリン受容体モジュレーターとしての使用
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
EP2350052B1 (en) * 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US9063126B2 (en) 2008-09-29 2015-06-23 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US20110294668A1 (en) 2008-12-08 2011-12-01 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
WO2010094695A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
CA2782361C (en) 2009-12-17 2018-01-16 Abbott Laboratories Bridgehead amine ring-fused indoles and indolines useful to treat neurodegenerative and neuropsychiatric disorders
WO2011084433A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
US8809532B2 (en) 2009-12-17 2014-08-19 Abbvie Inc. Aza-ring fused indole and indoline derivatives
US9174949B2 (en) 2010-01-07 2015-11-03 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012101263A1 (en) * 2011-01-28 2012-08-02 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
BR112013019011B1 (pt) * 2011-01-28 2021-10-13 4Sc Discovery Gmbh Inibidores de il17 e ifn-gama, e seu uso
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
WO2013018695A1 (ja) 2011-07-29 2013-02-07 武田薬品工業株式会社 複素環化合物
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015067648A1 (de) * 2013-11-05 2015-05-14 Bayer Cropscience Ag Neue verbindungen zur bekämpfung von arthropoden
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
EP3759095A1 (en) 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
WO2020007729A1 (en) * 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as gpr142 agonists
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
KR20220099970A (ko) 2019-10-11 2022-07-14 인사이트 코포레이션 Cdk2 억제제로서의 이환식 아민
WO2022188792A1 (zh) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
KR20240107099A (ko) 2021-11-19 2024-07-08 닛뽕소다 가부시키가이샤 2-알킬싸이오-1-이미다조일에타논 화합물의 제조 방법
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
JP3418624B2 (ja) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
CA2327185A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
JP2002527134A (ja) 1998-10-13 2002-08-27 ソマネティクス コーポレイション 多チャンネル無侵襲組織オキシメータ
ES2200566T3 (es) 1998-10-23 2004-03-01 Dow Agrosciences Llc 3-(piridilo sustituido)-1,2,4-triazoles insecticidas.
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
PL1618092T3 (pl) 2003-05-01 2011-02-28 Bristol Myers Squibb Co Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy

Also Published As

Publication number Publication date
MY143000A (en) 2011-02-14
DK1725544T3 (da) 2009-07-27
UA85702C2 (ru) 2009-02-25
ECSP066833A (es) 2006-11-24
KR20060129077A (ko) 2006-12-14
RS50796B (sr) 2010-08-31
US7514458B2 (en) 2009-04-07
PL1725544T3 (pl) 2009-10-30
ZA200606177B (en) 2008-12-31
WO2005090333A8 (en) 2006-08-24
AU2005223738A1 (en) 2005-09-29
SI1725544T1 (sl) 2009-10-31
EA011634B1 (ru) 2009-04-28
WO2005090333A1 (en) 2005-09-29
BRPI0508561A (pt) 2007-08-14
HRP20090334T1 (en) 2009-07-31
US7214802B2 (en) 2007-05-08
NZ550148A (en) 2010-07-30
JP4850824B2 (ja) 2012-01-11
NO20064120L (no) 2006-09-26
CA2557856A1 (en) 2005-09-29
JP2007528395A (ja) 2007-10-11
US20060079519A1 (en) 2006-04-13
CY1109333T1 (el) 2014-07-02
PE20051146A1 (es) 2006-02-02
EP1887003A1 (en) 2008-02-13
DE602005014621D1 (de) 2009-07-09
CA2557856C (en) 2010-06-29
CN1930144A (zh) 2007-03-14
IL177937A0 (en) 2006-12-31
EP1725544B1 (en) 2009-05-27
US20070142371A1 (en) 2007-06-21
AU2005223738B2 (en) 2011-08-11
PT1725544E (pt) 2009-07-02
ATE432273T1 (de) 2009-06-15
TW200602313A (en) 2006-01-16
ES2327940T3 (es) 2009-11-05
EA200601571A1 (ru) 2007-02-27
EP1725544A1 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
AR054799A1 (es) Derivados de oxindol
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
AR078786A1 (es) Derivados de la cromenona
AR023703A1 (es) N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure